Accessibility Menu
Evolus logo

Evolus(NASDAQ) EOLS

Market Cap$568.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-29%
5 Year-21%
1 Year+21%
1 Month+55%
$8.61
+5.20%
+0.43Today
After hours$8.55-$0.05 (-0.64%)
Evolus last closing stock price
MetricPriceDate
Last closeUSD 8.602026-08-19
Evolus stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.91%USD 8.122026-08-12
1 month+55.09%USD 5.552026-07-20
3 month+33.33%USD 6.452026-05-21
Year to date+29.32%USD 6.652025-12-31
1 year+20.62%USD 7.132025-08-19
3 year-9.66%USD 9.522023-08-18
5 year-20.66%USD 10.842021-08-20
Since inception-28.87%USD 11.502018-02-08

Evolus Financials at a Glance

Market Cap

$568.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$316.49M

Net Income (TTM)

-$34.33M

EPS (TTM)

-$0.53

P/E Ratio

-16.32

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$8.61

Volume

964,004.338

Open

$8.22

Previous Close

$8.60

Daily Range

$8.22 - $8.69

52-Week Range

$3.86 - $8.69

Estimated Earnings Date

Nov 4, 2026

EOLS News

Beauty stocks - GettyImages-1055890872

Why Evolus Stock Soared Today

Joe TenebrusoMar 4, 2026
Foolcom-Featured.png

Evolus (EOLS) Q2 Revenue Rises 4%

Motley Fool Markets TeamAug 6, 2025
Physician with a patient with masks

Why Shares of Evolus Are Jumping Thursday

James HalleyJul 27, 2023
Group of medical practitioners having a seminar in board room

Why Evolus Shares Jumped This Week

James HalleyJan 20, 2023
plastic surgery

Can Evolus Disrupt the Botox Market?

Brett SchaferJul 3, 2021
GettyImages-184600247

Why Evolus Stock Dived by Almost 19% Today

Eric VolkmanApr 22, 2021
GettyImages-612737000

Here's Why Evolus Stock Tumbled 17.4% Today

Todd CampbellMay 16, 2019
Oil pump GettyImages-467119309

Why Penn Virginia, Evolus, and Cousins Properties Slumped Today

Dan CaplingerMar 25, 2019
Page 1

EOLS: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evolus

Evolus, Inc. makes beauty products that help people smooth out frown lines. It sells medical treatments directly to doctors who perform cosmetic procedures. These products serve customers who pay out of pocket for their own aesthetic improvements.

What Is in the Beauty Bag?

  • Jeuveau: Purified botulinum toxin type A treatment used to temporarily smooth moderate to severe frown lines.
  • Evolysse: Collection of injectable hyaluronic acid gels used for various facial aesthetic treatments.
  • Profhilo: Injectable hyaluronic acid product for skin-quality applications licensed for future distribution in the United States.
  • Service Revenue: Income generated through a distribution partner for product sales in Canada.

Strategic Moves and Global Growth

  • Licensed Profhilo from IBSA Institut Biochimique SA in July 2026 for exclusive U.S. distribution.
  • Expanded a deal with Symatese in August 2026 to sell injectable gels in Europe, Canada, and Australia.
  • Launched a collection of injectable hyaluronic acid gels in Europe during May 2026.
  • Anticipated U.S. regulatory approval for new injectable gel products in 2026 and 2027.

A Focus on Cash Payments

The company focuses only on products that patients pay for directly without using insurance. This strategy avoids the complex rules and paperwork of the medical reimbursement system.

A Look at the Numbers

  • Net revenues rose 21.2% to $84.1 million in the three months ended June 30, 2026.
  • Gross profit margin reached 68.0% in the three months ended June 30, 2026.
  • Net loss was $18.7 million in the six months ended June 30, 2026, down from $36.0 million.
  • Selling, general and administrative expenses fell 3.8% in the six months ended June 30, 2026.
  • Cash and cash equivalents totaled $45.2 million as of June 30, 2026.

The Bottom Line

Evolus has evolved from a single-product business into a multi-product beauty company with international reach. Its focus on products patients pay for directly allows it to use flexible pricing to grow its customer base.

AI Generated • Aug 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

334

CEO

David Moatazedi, MBA

Website

www.evolus.com

Headquarters

Newport Beach, CA 92660, US

EOLS Financials

Key Financial Metrics (TTM)

Gross Margin

66.25%

Operating Margin

-7.33%

Net Income Margin

-10.85%

Return on Equity

123.11%

Return on Capital

-28.51%

Return on Assets

-13.84%

Earnings Yield

-6.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$568.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

66.05M

Volume

964.00K

Avg. Volume

846.98K

Financials (TTM)

Gross Profit

$209.67M

Operating Income

-$23.20M

EBITDA

-$10.23M

Operating Cash Flow

-$15.38M

Capital Expenditure

-$4.79M

Free Cash Flow

-$20.17M

Cash & ST Invst.

$45.17M

Total Debt

$164.80M

Evolus Performance Analysis

Evolus annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 148,616,00049.1%
20232023-12-31USD 202,085,00036.0%
20242024-12-31USD 266,274,00031.8%
20252025-12-31USD 297,176,00011.6%
Evolus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-0.6%
Q42025-12-3130.9%
Q12026-03-31-19.0%
Q22026-06-3015.0%
Evolus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3341.1%
20232023-12-31USD -1.08-18.3%
20242024-12-31USD -0.81-25.0%
20252025-12-31USD -0.80-1.5%
Evolus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3011.1%
Q42025-12-31100.8%
Q12026-03-31-8100.0%
Q22026-06-3025.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$84.08M

+21.2%

Gross Profit

$57.18M

+26.2%

Gross Margin

68.00%

N/A

Market Cap

$568.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.62M

N/A

Employees

350

N/A

Net Income

-$8.05M

+53.0%

EBITDA

-$4.03M

+48.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$45.17M

-26.8%

Total Debt

$164.80M

+6.4%

Accounts Receivable

$62.38M

+30.8%

Inventory

$40.90M

+54.6%

Long Term Debt

$162.23M

+6.4%

Short Term Debt

$2.57M

+7.6%

Return on Assets

-13.84%

N/A

Return on Invested Capital

-15.54%

N/A

Free Cash Flow

-$2.36M

+91.3%

Operating Cash Flow

-$3.59M

+85.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NGNENeurogene Inc.
$39.43+10.54%
TOIThe Oncology Institute, Inc.
$5.13-19.72%
AUTLAutolus Therapeutics plc
$2.54+10.92%
KIDSOrthoPediatrics Corp.
$26.50+3.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$174.38+1.77%
BITOProShares Trust - ProShares Bitcoin ETF
$9.25+0.06%
IBITiShares Bitcoin Trust
$38.78+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.19+0.08%

Questions About EOLS

What is the current price of Evolus?

Evolus is trading at $8.60 per share.

What is the 52-week range for Evolus?

Over the past 52 weeks, Evolus has traded between $3.86 and $8.69.

How much debt does Evolus have?

As of the most recent reporting period, Evolus reported total debt of $164.80M.

How much cash does Evolus have on hand?

Evolus reported $45.17M in cash and cash equivalents in its most recent financial results.

What is Evolus’s dividend yield?

Evolus does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services